Gerald W Valentine1,2, Kathryn Hefner1,2, Peter I Jatlow1,3, Robert A Rosenheck1,2, Ralitza Gueorguieva4, Mehmet Sofuoglu1,2. 1. a Department of Psychiatry , Yale School of Medicine , New Haven , Connecticut , USA. 2. b Veterans Health Administration Mental Illness Research, Education and Clinical Center (MIRECC) , West Haven , Connecticut , USA. 3. c Department of Laboratory Medicine , Yale School of Medicine , New Haven , Connecticut , USA. 4. d Department of Biostatistics , Yale School of Public Health , New Haven , Connecticut , USA.
Abstract
OBJECTIVE: Compared to the general U.S. population, smokers with comorbid psychiatric and/or substance use disorders have lower quit rates after evidence-based treatments and disproportionately high smoking-related deaths. Improved modalities for reducing tobacco-related harm in this subpopulation are needed. Because electronic cigarettes (e-cigarettes) can now deliver physiologically relevant levels of nicotine to consumers, they represent an additional nicotine delivery system that could be used in cessation interventions. While current data suggest that the use of e-cigarettes by smokers promotes a reduction in combustible cigarette use, smoking quit rates through use of e-cigarettes appears to be low. The goal of this study was to examine impact of e-cigarette use on combustible tobacco use as well as on the readiness to quit smoking and changes in nicotine dependence in a multimorbid population. METHODS: We conducted a 4-week, open-label study in 43 military veteran smokers who had no immediate intention to stop smoking and were currently receiving psychiatric services from the Department of Veterans Affairs health care system. Participants were provided with a study e-cigarette they could use ad libitum along with other tobacco products and were encouraged to attend weekly laboratory visits and a one-month follow-up visit. Main outcome measures were number of cigarettes smoked per day (CPD), the frequency of e-cigarette use, the amount of money spent on combustible cigarettes (U.S. dollars/week), alveolar carbon monoxide (CO) levels, and urine cotinine levels. RESULTS: Mean e-cigarette use was 5.7 days per week and only 9% of participants used the e-cigarette for fewer than 4 days per week. Significant reductions in breath CO (9.3 ppm to 7.3 ppm, p < .02) and CPD (from 16.6 to 5.7, p < .001) were observed across study weeks, and no serious adverse events were reported. Three participants (10% of completers) reported smoking cessation that was corroborated biochemically. At one-month follow-up, motivation to quit smoking remained significantly higher and the level of nicotine dependence was significantly lower than at baseline. CONCLUSIONS: E-cigarettes are acceptable to smokers with psychiatric comorbidities, as indicated by sustained and frequent e-cigarette use by 90% of participants, and may promote reduction and/or cessation of combustible cigarette use. E-cigarettes appear to be a viable harm reduction modality in smokers with psychiatric comorbidities.
OBJECTIVE: Compared to the general U.S. population, smokers with comorbid psychiatric and/or substance use disorders have lower quit rates after evidence-based treatments and disproportionately high smoking-related deaths. Improved modalities for reducing tobacco-related harm in this subpopulation are needed. Because electronic cigarettes (e-cigarettes) can now deliver physiologically relevant levels of nicotine to consumers, they represent an additional nicotine delivery system that could be used in cessation interventions. While current data suggest that the use of e-cigarettes by smokers promotes a reduction in combustible cigarette use, smoking quit rates through use of e-cigarettes appears to be low. The goal of this study was to examine impact of e-cigarette use on combustible tobacco use as well as on the readiness to quit smoking and changes in nicotine dependence in a multimorbid population. METHODS: We conducted a 4-week, open-label study in 43 military veteran smokers who had no immediate intention to stop smoking and were currently receiving psychiatric services from the Department of Veterans Affairs health care system. Participants were provided with a study e-cigarette they could use ad libitum along with other tobacco products and were encouraged to attend weekly laboratory visits and a one-month follow-up visit. Main outcome measures were number of cigarettes smoked per day (CPD), the frequency of e-cigarette use, the amount of money spent on combustible cigarettes (U.S. dollars/week), alveolar carbon monoxide (CO) levels, and urine cotinine levels. RESULTS: Mean e-cigarette use was 5.7 days per week and only 9% of participants used the e-cigarette for fewer than 4 days per week. Significant reductions in breath CO (9.3 ppm to 7.3 ppm, p < .02) and CPD (from 16.6 to 5.7, p < .001) were observed across study weeks, and no serious adverse events were reported. Three participants (10% of completers) reported smoking cessation that was corroborated biochemically. At one-month follow-up, motivation to quit smoking remained significantly higher and the level of nicotine dependence was significantly lower than at baseline. CONCLUSIONS: E-cigarettes are acceptable to smokers with psychiatric comorbidities, as indicated by sustained and frequent e-cigarette use by 90% of participants, and may promote reduction and/or cessation of combustible cigarette use. E-cigarettes appear to be a viable harm reduction modality in smokers with psychiatric comorbidities.
Authors: Claire Adams Spears; Dina M Jones; Scott R Weaver; Bo Yang; Terry F Pechacek; Michael P Eriksen Journal: Addiction Date: 2018-11-05 Impact factor: 6.526
Authors: Andrea H Weinberger; Jiaqi Zhu; Jessica L Barrington-Trimis; Katarzyna Wyka; Renee D Goodwin Journal: Nicotine Tob Res Date: 2020-10-08 Impact factor: 4.244
Authors: Jenny E Ozga-Hess; Nicholas J Felicione; Stuart G Ferguson; Geri Dino; Daniel Elswick; Catherine Whitworth; Nicholas Turiano; Melissa D Blank Journal: Addict Behav Date: 2019-08-21 Impact factor: 3.913
Authors: Stephen T Higgins; Allison N Kurti; Marissa Palmer; Jennifer W Tidey; Antonio Cepeda-Benito; Maria R Cooper; Nicolle M Krebs; Lourdes Baezconde-Garbanati; Joy L Hart; Cassandra A Stanton Journal: Prev Med Date: 2019-05-02 Impact factor: 4.018
Authors: Claire Adams Spears; Dina M Jones; Scott R Weaver; Bo Yang; Terry F Pechacek; Michael P Eriksen Journal: Drug Alcohol Depend Date: 2020-05-13 Impact factor: 4.492
Authors: Christine F McDonald; Stuart Jones; Lutz Beckert; Billie Bonevski; Tanya Buchanan; Jack Bozier; Kristin V Carson-Chahhoud; David G Chapman; Claudia C Dobler; Juliet M Foster; Paul Hamor; Sandra Hodge; Peter W Holmes; Alexander N Larcombe; Henry M Marshall; Gabrielle B McCallum; Alistair Miller; Philip Pattemore; Robert Roseby; Hayley V See; Emily Stone; Bruce R Thompson; Miranda P Ween; Matthew J Peters Journal: Respirology Date: 2020-07-26 Impact factor: 6.424